Macrolides versus placebo for chronic asthma

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 11, 2021, Pages

  Undela, Krishna ^a   Goldsmith, Lucy ^b   Kew, Kayleigh M ^c   Ferrara, Giovanni ^d  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c Cochrane ^*  (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; MACROLIDE; PLACEBO; STEROID; ANTIINFECTIVE AGENT;

ADULT; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; CHILD; CLINICAL OUTCOME; DISEASE EXACERBATION; DISEASE MANAGEMENT; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; EMERGENCY CARE; EMERGENCY WARD; EOSINOPHIL COUNT; EVIDENCE BASED MEDICINE; FIXED EFFECT MODEL; FORCED EXPIRATORY VOLUME; GRADE APPROACH; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; PEAK EXPIRATORY FLOW; PEDIATRIC PATIENT; PROTEIN BLOOD LEVEL; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESPIRATORY TRACT ALLERGY; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SPUTUM; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT DURATION; MIDDLE AGED; QUALITY OF LIFE; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; ASTHMA; DISEASE PROGRESSION; HUMANS; MACROLIDES; MIDDLE AGED; QUALITY OF LIFE; YOUNG ADULT;

EID: 85119697613     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002997.pub5     Document Type: Review

References (114)

1. Amayasu H, Yashida S, Ebana S, Yamamoto Y, Nishikawa T, Shoji T, et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology 2000;84(6):594-8. x-wiley/crsRef/3242787
2. Belotserkovskaya Y, Sinopalnikov A. Open-trial randomized comparative trial of the efficacy of the azithromycin in the 8 week treatment of mild to moderate asthma. European Respiratory Journal 2007;30(Suppl 51):358s. x-wiley/crsRef/3242789
3. Black P, Jenkins CR, Scicchitano R, Blasi F, Allegra L, Mills G, et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine 2001;164(4):536-41. x-wiley/crsRef/3242791
4. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68(4):322-9. x-wiley/crsRef/3242793
5. Cameron EJ, Chaudhuri R, Mair F, McSharry C, Greenlaw N, Weir CJ, et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal 2013;42(5):1412-5. x-wiley/crsRef/17142030
6. ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). x-wiley/crsRef/17142033
7. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hidge S, James AL, et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine 2017;195:A4679. x-wiley/crsRef/17142032
8. Gibson PG, Yang IA, Upham PN, Hodge S, James AL, Jenkins C, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017;390(10095):659-68. x-wiley/crsRef/17142034
9. Hahn DL, Plane MB, Mahdi OS, Byrne GI. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials 2006;1(2):e11. x-wiley/crsRef/3242797
10. Hahn D, Grasmick M, Hetzel S. Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal 2011;38:322s. x-wiley/crsRef/3242799
11. Hahn DL, Grasmick M, Hetzel S, Yale S. Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine 2012;25(4):442-59. x-wiley/crsRef/3242800
12. He J, Zhu N, Chen XD. Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science 2009;36(6):719-22. x-wiley/crsRef/3242802
13. Kamada AK, Hill MR, Iklé DN, Brenner AM, Szefler SJ. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology 1993;91(4):873-82. x-wiley/crsRef/3242804
14. Kapoor S, Brashier B, Udupa A, Pawar R, Kodgule R, Limaye S, et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal 2010;36(suppl 54):P1176. x-wiley/crsRef/3242806
15. Kostadima E, Tsiodras S, Alexopoulos EI, Kaditis AG, Mavrou I, Georgatou N, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal 2004;23(5):714-7. x-wiley/crsRef/3242808
16. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002;121(6):1782-8. x-wiley/crsRef/3242810
17. Nelson HS, Hamilos DL, Corsello PR, Levesque NV, Buchmeier AD, Bucker BL. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease 1993;147(2):398-404. x-wiley/crsRef/3242812
18. Piacentini GL, Peroni DG, Bodini A, Pigozzi R, Costella S, Loiacono A, et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings 2007;28(2):194-8. x-wiley/crsRef/3242814
19. Shoji T, Yoshida S, Sakamoto H, Hasegawa H, Nakagawa H, Amayasu H. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy 1999;29(7):950-6. x-wiley/crsRef/3242816
20. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). x-wiley/crsRef/3242818
21. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology 2007;12:A120. x-wiley/crsRef/3242820
22. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. x-wiley/crsRef/3242819
23. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine 2008;177(2):148-55. x-wiley/crsRef/3242821
24. Strunk RC, Bacharier LB, Phillips BR, Szefler SJ, Zeiger RS, Chinchilli VM, et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology 2008;122(6):1138-44.e4. x-wiley/crsRef/3242823
25. Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology 2010;126(4):747-53. x-wiley/crsRef/3242825
26. Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology 2016;7(3):e131-4. x-wiley/crsRef/17142036
27. Wang Y, Zhang SL, Qu Y. Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine 2012;17(11):1948-51. x-wiley/crsRef/3242827
28. Wang T, Pei FY, Song XP, Wang Q. Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China 2014;11(9):122-4. x-wiley/crsRef/3242829
29. Xiao KA. The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine 2013;11:119-20. x-wiley/crsRef/3242831
30. Yan XQ, Wu LQ, Lin J, Xiao XD, Dai YR. Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics 2008;13(2):184-7. x-wiley/crsRef/3242833
31. Zhang LY, Qian Q. Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal 2013;25:159-60. x-wiley/crsRef/3242835
32. Andrade WP, Renard RL, Nelson HS. The effect of troleandomycin and methylprednisolone alone and in combination on bronchial sensitivity to methacholine. Annals of Allergy 1983;51(5):515-7. x-wiley/crsRef/3242837
33. Anonymous. Bronchial asthma – clarithromycin depresses neutrophil inflammation [Asthma bronchiale – clarithromycin senkt die neutrophile Entzündung]. Pneumologie 2009;63(1):2. x-wiley/crsRef/3242839
34. Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA 2015;19:2034-44. x-wiley/crsRef/17142038
35. Beigelman A, Isaacson-Schmid M, Sajol G, Baty J, Rodriguez OM, Leege E, et al. Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. Journal of Allergy and Clinical Immunology 2015;135(5):1171-78e1. x-wiley/crsRef/17142040
36. Ball BD, Hill MR, Brenner M, Sanks R, Szefler SJ. Effect of low-dose troleandromycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Annals of Allergy 1990;65(1):37-45. x-wiley/crsRef/3242841
37. Cogo R, Caiazzo G, De Luca P, Boddi V, De Luca M, Casini A. Effect of miocamycin and amoxicillin/clavulonate on total serum immunoglobulin E levels in patients with infectious exacerbations of allergic asthma: a crossover trial. Current Therapeutic Research 1994;55(2):184-98. x-wiley/crsRef/3242843
38. D'Azevedo Silveira V, Roza CA, Luisi F, Pitrez PM, Stein RT, Pinto LA. Azithromycin therapy in infants with bronchiolitis reduces recurrent wheezing 3 months after hospitalization: a randomized, placebo-controlled trial. Pediatric Pulmonology 2016;S9:59. x-wiley/crsRef/17142042
39. Ebling WF, Szefler SJ, WJ Jusko. Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate. Absence of effects of troleandomycin on ester hydrolysis. Journal of Chromatography 1984;305(2):271-80. x-wiley/crsRef/3242845
40. Feldman C, Anderson R, Theron AJ, Ramafi G, Cole PJ, Wilson R. Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. Inflammation 1997;21(6):655-65. x-wiley/crsRef/3242847
41. Gong L, Xu L, Diao M, Guo F, Bian FF, Min J, et al. Clinical effect of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin. European Review for Medical and Pharmacological Sciences 2016;20(24):5256-60. x-wiley/crsRef/17142044
42. Gotfried MH, Jung R, Messick CR, Rubinstein I, Garey KW, Rodvold KA, et al. Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: a randomized, double-blind, placebo-controlled pilot study. Current Therapeutic Research 2004;65(1):1-12. x-wiley/crsRef/3242849
43. Hodgson D, Anderson J, Reynolds C, Oborne J, Meakin G, Bailey H, et al. The effects of azithromycin in treatment-resistant cough: a randomized, double-blind, placebo-controlled trial. Chest 2016;149(4):1052-60. x-wiley/crsRef/17142046
44. Hueston WJ. A comparison of albuterol and erythromycin for the treatment of acute bronchitis. Journal of Family Practice 1991;33:476-80. x-wiley/crsRef/3242851
45. Itkin IH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. Journal of Allergy 1970;45(3):146-62. x-wiley/crsRef/3242853
46. Johnston SL, Szigeti M, Cross M, Brightling C, Chaudhuri R, Harrison T, et al. Azithromycin for acute exacerbations of asthma: the AZALEA randomized clinical trial. JAMA Internal Medicine 2016;176(11):1630-7. x-wiley/crsRef/17142048
47. Kaplan MA, Goldin M. The use of triacetyloleandomycin in chronic infectious asthma. Antibiotics Annual 1958;6:273-6. x-wiley/crsRef/3242855
48. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. European Respiratory Journal 1997;10(5):994-9. x-wiley/crsRef/3242857
49. Koutsoubari I, Papaevangelou V, Konstantinou GN, Makrinioti H, Xepapadaki P, Kafetzis D, et al. Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study. Pediatric Allergy and Immunology 2012;23(4):385-90. x-wiley/crsRef/3242859
50. Lee HB, Lee YC, Rhee YK. Effects of erythromycin and new macrolides on the serum theophylline level and clearance. Tuberculosis and Respiratory Diseases 1998;3:546-52. x-wiley/crsRef/17142050
51. Mandhane PJ, Paredes Zambrano de Silbernagel P, Aung YN, Williamson J, Lee BE, Spier S, et al. Treatment of preschool children presenting to the emergency department with wheeze with azithromycin: a placebo-controlled randomized trial. PloS One 2017;12(8):e0182411. x-wiley/crsRef/17142052 [DOI: 10.1371/journal.pone.0182411]
52. Oldach D, Luna C, Szabo P, Mitha I, Tanaseanu C, Doreski A, et al. Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma. European Respiratory Journal 2015;Suppl 59:PA2655. x-wiley/crsRef/17142054
53. Ram B, Aggarwal AN, Dhooria S, Sehgal IS, Garg M, Behera D, et al. A pilot RCT of nebulized amphotericin for maintenance of remission in patients with allergic bronchopulmonary aspergillosis. Journal of Asthma 2016;5:517-24. x-wiley/crsRef/17142056
54. Spector SL, Katz FH, Farr RS. Troleandomycin: effectiveness in steroid-dependent asthma and bronchitis. Journal of Allergy and Clinical Immunology 1974;54(6):367-79. x-wiley/crsRef/3242861
55. Stokholm J, Chawes BL, Vissing NH, Bjarnadottir E, Pedersen TM, Vinding RK, et al. Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine 2016;4(1):19-26. x-wiley/crsRef/17142058
56. Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, Jusko WJ. The effect of troleandomycin on methylprednisolone elimination. Journal of Allergy and Clinical Immunology 1980;66(6):447-51. x-wiley/crsRef/3242863
57. Szefler SJ, Brenner M, Jusko WJ, Spector SL, Flesher KA, Ellis EF. Dose- and time-related effect of troleandomycin on methylprednisolone elimination. Clinical Pharmacology and Therapeutics 1982;32(2):166-71. x-wiley/crsRef/3242865
58. Szefler SJ, Ellis EF, Brenner M, Rose JQ, Spector SL, Yurchak AM, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. Journal of Allergy and Clinical Immunology 1982;69(5):455-60. x-wiley/crsRef/3242867
59. Takamura M, Odashima Y, Iikura H. Continuous low-dosage macrolide therapy in children with bronchial asthma. Japanese Journal of Antibiotics 2001;54(Suppl C):9-11. x-wiley/crsRef/3242869
60. Wald JA, Friedman BF, Farr RS. An improved protocol for the use of troleandomycin (TAO) in the treatment of steroid-requiring asthma. Journal of Allergy and Clinical Immunology 1986;78(1 Pt 1):36-43. x-wiley/crsRef/3242871
61. Weinberger MW, Hudgel D, Spector S, Chidsey C. Inhibition of theophylline clearance by troleandomycin. Journal of Allergy and Clinical Immunology 1977;59(3):228-31. x-wiley/crsRef/3242873
62. Zeiger RS, Schatz M, Sperling W, Simon RA, Stevenson DD. Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma. Journal of Allergy and Clinical Immunology 1980;66(6):438-46. x-wiley/crsRef/3242875
63. NCT02517099. Preschool wheeze: Inflammation/Infection Guided Management (PrIGMa) [Use of pathological phenotype to determine optimal management for moderate to severe preschool wheeze]. www.clinicaltrials.gov/ct2/show/NCT02517099 (first received 6 August 2015). x-wiley/crsRef/17642982
64. Adachi T, Motojima S, Hirata A. Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. Journal of Allergy and Clinical Immunology 1996;98(6 Pt 2):S207-15.
65. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clinic Proceedings 1999;74(6):613-34.
66. ATS Scientific Assembly on Clinical Problems. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. American Review of Respiratory Disease 1987;136(1):225-44.
67. Black PN. Anti-inflammatory effects of macrolide antibiotics. European Respiratory Journal 1997;10:971-2.
68. Black PN, Scicchitano R, Jenkins CR, Blasi F, Allegra L, Wlodarczyk J, et al. Serological evidence of infection with Chlamidia pneumoniae is related to the severity of asthma. European Respiratory Journal 2000;15(2):254-9.
69. Brill SE, Law M, El-Emir E, Allinson JP, James P, Maddox V, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax 2015;70(10):930-8.
70. Smith D, Du Rand I, Addy CL, Collyns T, Hart SP, Mitchelmore PJ, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax 2020;75:370-404.
71. Cai Y, Chai D, Wang R, Bai N, Liang BB, Liu Y. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. Journal of Antimicrobial Chemotherapy 2011;66(5):968-78.
72. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. New England Journal of Medicine 2018;378(26):2486-96.
73. National Cancer Institute. Common Terminology Criteria for Adverse Events v.6. ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed prior to 14 November 2021).
74. Enright PL, Beck KC, Sherrill DL. Repeatability of spirometry in 18,000 adult patients. American Journal of Respiratory and Critical Care Medicine 2004;169:235-8. [DOI: 10.1164/rccm.200204-347OC]
75. Essilfie AT, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Beckett EL, et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 2015;70:458-67.
76. Fan H. Macrolides for asthma [personal communication]. Email to: Kayleigh Kew 30 July 2015.
77. Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No: CD010834. [DOI: 10.1002/14651858.CD010834.pub3]
78. Gencay M, Rudiger JJ, Tamm M, Solér M, Perruchoud AP, Roth M. Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma. American Journal of Respiratory and Critical Care Medicine 2001;163(5):1097-100.
79. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. ERJ Open Research 2019;5:00056-2019. [DOI: 10.1183/23120541.00056-2019]
80. Global Initiative for Asthma. Global strategy for asthma management and prevention (1995 version). ginasthma.org/wp-content/uploads/2019/01/1995-GINA.pdf (accessed 8 April 2015).
81. Global Initiative for Asthma. Global strategy for asthma management and prevention (2002 version). ginasthma.org/wp-content/uploads/2019/01/2002-GINA.pdf (accessed 8 April 2015).
82. Global Initiative for Asthma. Global strategy for asthma management and prevention (2007 update). ginasthma.org/wp-content/uploads/2019/01/2007-GINA.pdf (accessed 8 April 2015).
83. Global Initiative for Asthma. Global strategy for asthma management and prevention (update 2010). ginasthma.org/wp-content/uploads/2019/01/2010-GINA.pdf (accessed 8 April 2015).
84. Global Initiative for Asthma. Global strategy for asthma management and prevention (update 2014). ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf (accessed 8 April 2015).
85. Global Initiative for Asthma. Global strategy for asthma management and prevention 2020. ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf (accessed prior to 20 May 2021).
86. Global Initiative for Asthma. Global strategy for asthma management and prevention 2021. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed prior to 14 November 2021.
87. McMaster University (developed by Evidence Prime) GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org (accessed 27 June 2021).
88. Hansbro PM, Starkey MR, Mattes J, Horvat JC. Pulmonary immunity during respiratory infections in early life and the development of severe asthma. Annals of the American Thoracic Society 2014;11(Suppl 5):S297-302.
89. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
90. Hiles SA, McDonald VM, Guilhermino M, Bruselle GG, Gibson PG. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. European Respiratory Journal 2019;54(5):1901381. [DOI: 10.1183/13993003.01381-2019]
91. Hinks T, Levine SJ, Brusselle GG. Treatment options in type-2 low asthma. European Respiratory Journal 2012;57(1):2000528.
92. Jadad A, Moore RA, Carroll D, Jenkson C, Reynolds JM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996;17(1):1-12.
93. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. Journal of Clinical Epidemiology 1994;47(1):81-7.
94. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respiratory Medicine 2005;99:553-8.
95. Kawasaki S, Takizawa H, Ohtoshi T, Takeuchi N, Kohyama T, Nakamura H, et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrobial Agents and Chemotherapy 1998;42(6):1499-502.
96. Konno S, Asano K, Kurokawa M, Ikeda K, Okamoto K, Adachi M. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. International Archives of Allergy and Immunology 1994;105(3):308-16.
97. Koyama T, Takizawa H, Kawasaki S, Takami K, Otoshi T, Ito K. Effects of various drugs on IL-8 production by eosinophils collected from patients with allergic inflammation. Japanese Journal of Antibiotics 1998;51(Suppl A):131-3.
98. Kraft M, Cassell GH, Henson JE, Watson H, Williamson J, Marmion BP, et al. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. American Journal of Respiratory and Critical Care Medicine 1998;158(3):998-1001.
99. Malhotra-Kumar S, Lammens C, Coenen S, van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007;369(9560):482-90.
100. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]
101. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No: CD003559. [DOI: 10.1002/14651858.CD003559.pub4]
102. Olin JT, Wechsler ME. Asthma: pathogenesis and novel drugs for treatment. BMJ 2014;349:g5517.
103. Pasternack R, Huhtala H, Karjalainen J. Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: a longitudinal analysis. Journal of Allergy and Clinical Immunology 2005;116(5):1123-8.
104. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. New England Journal of Medicine 2018;378(26):2475-85.
105. Reiter J, Demirel N, Mendy A, Gasana J, Vieira ER, Colin AA, et al. Macrolides for the long-term management of asthma – a meta-analysis of randomized clinical trials. Allergy 2013;68(8):1040-9.
106. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
107. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). In: Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
108. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. European Respiratory Journal 2013;42(1):239-51.
109. Tong X, Guo T, Liu S, Peng S, Yan S, Yang X, et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics 2015;31:99-108.
110. Wang X, Luo J, Wang D, Liu B, Liu C. The efficacy and safety of long-term add-on treatment of azithromycin in asthma: a systematic review and meta-analysis. Medicine 2019;98(38):e17190.
111. Wood PR, Hill VL, Burks ML, Peters JI, Singh H, Kannan TR, et al. Mycoplasma pneumoniae in children with acute and refractory asthma. Annals of Allergy, Asthma and Immunology 2013;110(5):328-334.e1.
112. Kew KM, Undela K, Kotortsi I, Ferrara G. Macrolides for chronic asthma. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No: CD002997. [DOI: 10.1002/14651858.CD002997.pub4]
113. Richeldi L, Ferrara G, Fabbri LM, Gibson PG. Macrolides for chronic asthma. Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No: CD002997. [DOI: 10.1002/14651858.CD002997]
114. Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No: CD002997. [DOI: 10.1002/14651858.CD002997.pub2]